Live Analyst Rating Changes 1527 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Josh Jennings
TD
Josh Jennings
Wall Street Analyst
★☆☆☆☆
#2450
on 13Foresight · ranked by our own returns
36%
Success Rate
-10.7%
Average Return
18 of 50 calls profitable · -16.9% vs benchmark
📈 Across the calls we could measure, roughly 36% of Josh Jennings's ratings turned a profit when each position was held for 2 year — averaging -10.7% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

296 Buy 21 Hold 0 Sell
Josh's Stock Coverage 40 ratings · 2026-06-21
Company Date Position Consensus Price Target 2-Yr Return
RCEL
Avita Medical
Jun 18, 2026 BUY Strong Buy
+154.7% avg upside
10 analysts
$5.50
37.16% Upside
·
BFLY
Butterfly Network
Jun 18, 2026 BUY Strong Buy
-48.9% avg upside
7 analysts
$6.00
32.52% Downside
·
ESTA
Establishment Labs Holdings
Jun 18, 2026 BUY Strong Buy
-1.6% avg upside
12 analysts
$100.00
17.86% Upside
+0.0%
HUMA
Humacyte
Jun 17, 2026 BUY Strong Buy
+665.4% avg upside
11 analysts
$1.25
35.22% Upside
·
BSX
Boston Scientific
Jun 16, 2026 BUY Strong Buy
+72.9% avg upside
38 analysts
$61.00
34.70% Upside
-3.5%
VCEL
Vericel
Jun 10, 2026 BUY Strong Buy
+13.9% avg upside
16 analysts
$55.00
37.17% Upside
·
DXCM
Dexcom
Jun 10, 2026 BUY Strong Buy
+38.6% avg upside
32 analysts
$95.00
31.10% Upside
-2.1%
ABT
Abbott Laboratories
Jun 09, 2026 BUY Strong Buy
+31.2% avg upside
35 analysts
-3.1%
SENS
Senseonics Holdings
Jun 09, 2026 BUY Strong Buy
+124.8% avg upside
13 analysts
·
CBLL
Ceribell, Inc.
Jun 08, 2026 BUY Strong Buy
+38.7% avg upside
8 analysts
$29.00
60.76% Upside
-4.7%
MDT
Medtronic
Jun 04, 2026 BUY Buy
+23.5% avg upside
38 analysts
$119.00
49.95% Upside
-3.2%
EW
Edwards Lifesciences
Jun 03, 2026 BUY Strong Buy
+11.7% avg upside
34 analysts
$104.00
19.15% Upside
+0.8%
PRCT
PROCEPT BioRobotics
Jun 01, 2026 BUY Strong Buy
+79.5% avg upside
16 analysts
$34.00
56.59% Upside
-19.8%
BDX
Becton Dickinson
May 29, 2026 HOLD Buy
+35.5% avg upside
25 analysts
$163.00
13.22% Upside
-1.4%
CERS
Cerus
May 27, 2026 BUY Strong Buy
+99.1% avg upside
10 analysts
$5.00
85.15% Upside
+0.0%
MDWD
Mediwound
May 27, 2026 BUY Strong Buy
+51.7% avg upside
13 analysts
$25.00
75.59% Upside
-0.6%
BAX
Baxter International
May 18, 2026 HOLD Hold
+49.6% avg upside
23 analysts
$20.00
0.60% Upside
+17.0%
TMDX
TransMedics Group
May 13, 2026 BUY Strong Buy
+50.5% avg upside
15 analysts
$120.00
52.38% Upside
+22.8%
STXS
Stereotaxis
May 13, 2026 BUY Strong Buy
+126.1% avg upside
7 analysts
$5.00
166.03% Upside
-3.8%
OBIO
Orchestra BioMed Holdings
May 13, 2026 BUY Strong Buy
+232.1% avg upside
9 analysts
$15.00
275.84% Upside
+1.2%
AVR
Anteris Technologies Global Corp.
May 13, 2026 BUY Strong Buy
+49.3% avg upside
5 analysts
$15.00
53.46% Upside
+49.8%
OM
Outset Medical
May 08, 2026 BUY Buy
+231.0% avg upside
8 analysts
$10.00
98.10% Upside
-1.9%
JNJ
Johnson & Johnson
Apr 23, 2026 BUY Strong Buy
-3.5% avg upside
36 analysts
$250.00
9.44% Upside
-0.4%
ATEC
Alphatec Holdings
Jan 23, 2026 BUY Strong Buy
+112.9% avg upside
22 analysts
$20.00
127.01% Upside
-48.2%
PODD
Insulet
Dec 04, 2025 BUY Strong Buy
+79.0% avg upside
32 analysts
$379.00
159.94% Upside
-53.9%
RBOT
Vicarious Surgical
Nov 13, 2025 BUY Buy
+5334.8% avg upside
6 analysts
-93.2%
SYK
Stryker
Nov 13, 2025 BUY Strong Buy
+24.0% avg upside
36 analysts
$435.00
41.25% Upside
-18.9%
ALURD
Allurion Technologies
Nov 12, 2025 BUY Strong Buy
-19.8% avg upside
1 analyst
$6.00
19.82% Downside
·
TNDM
Tandem Diabetes Care
Nov 06, 2025 BUY Strong Buy
+116.0% avg upside
29 analysts
$20.00
30.66% Upside
+26.8%
ZBH
Zimmer Biomet Holdings
Nov 05, 2025 HOLD Buy
+27.6% avg upside
37 analysts
$99.00
12.52% Upside
+1.9%
CTSO
Cytosorbents
Jan 12, 2024 HOLD Strong Buy
+2611.9% avg upside
13 analysts
-29.5%
ARAY
Accuray
Jan 12, 2024 HOLD Strong Buy
+1689.3% avg upside
9 analysts
-69.3%
TSE:PRN
Profound Medical
Oct 16, 2023 BUY Strong Buy
+96.8% avg upside
11 analysts
$25.47
165.41% Upside
·
ELUT
Elutia
Mar 04, 2022 BUY Strong Buy
+664.1% avg upside
5 analysts
$13.00
1126.37% Upside
-42.8%
GILD
Gilead Sciences
Oct 29, 2020 BUY Strong Buy
-4.8% avg upside
66 analysts
$80.00
35.27% Downside
+48.1%
VIVE
Viveve Medical
Nov 09, 2018 BUY Buy
+79999900.0% avg upside
8 analysts
$400.00
199999899.98% Upside
-99.8%
OCGN
Ocugen
Sep 27, 2018 BUY Strong Buy
+645.9% avg upside
17 analysts
$3.50
182.23% Upside
-99.1%
ADYX
Adynxx
Aug 10, 2017 BUY Strong Buy
+338749899.9% avg upside
4 analysts
$0.75
74999900.03% Upside
·
NUWE
Nuwellis
Mar 18, 2015 BUY Strong Buy
+16978.6% avg upside
7 analysts
$9.00
6641.53% Upside
-97.4%
IMRSQ
IMRIS
Aug 30, 2013 BUY Strong Buy
+3452280.9% avg upside
3 analysts
$3.50
4166566.71% Upside
·
🔒 35 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Josh Jennings — Frequently Asked Questions
How accurate are Josh Jennings's stock ratings?
Based on the calls 13Foresight could measure, about 36% of Josh's ratings were profitable over a one-year hold, with an average return of -9.2% per rating, or -13.2% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Josh ranked on 13Foresight?
Josh Jennings is currently ranked #2450 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Josh cover?
Josh most recently has ratings on RCEL, BFLY, ESTA, HUMA, BSX, VCEL, DXCM, ABT, SENS, CBLL, MDT, EW and 28 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.